Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron, dexmedetomidine and nitroglycerin added to lidocaine in Bier block for upper limb fractures
IRCT20101211005362N32Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of lidocaine, ondansetron, dexmedetomidine and nitroglycerin in upper extremity fracture (4 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Sensory block characteristics, Motor block characteristics and 1 more. Started Mar 2025; status: completed.
02
Drugs
lidocaineondansetrondexmedetomidinenitroglycerin
03
Conditions
upper extremity fracture
Beyond the preview
Go deeper on IRCT20101211005362N32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20101211005362N32.